Products
In many countries, there are no drugs containing carisoprodol on the market. In other countries, it is available in tablet form (Soma, Somadril). It has been approved in the United States since 1959. In 2007, the European Medicines Agency concluded that the benefits of the drug did not outweigh the risks.
Structure and properties
Carisoprodol (C12H24N2O4, Mr = 260.3 g/mol) is a carbamate. It exists as a white crystalline powder with a typical odor and a bitter taste that is sparingly soluble in water. Carisoprodol is a racemate.
Effects
Carisoprodol (ATC M03BA02) has central muscle relaxant, antianxiety, relaxant, and depressant properties. It is a prodrug of the active metabolite meprobamate. Carisoprodol has a half-life of 2 hours and meprobamate of 10 hours.
Indications
For short-term treatment of acute, painful musculoskeletal disorders (eg, back pain).
Dosage
According to the SmPC. Tablets are taken up to four times daily.
Abuse
Carisoprodol can be abused as a depressant intoxicant. Because of the health risks, this is strongly discouraged. An overdose is life-threatening.
Contraindications
- Hypersensitivity
- Acute intermittent porphyria
For complete precautions, see the drug label.
Interactions
The active metabolite meprobamate is formed by CYP2C19 and corresponding drug-drug interactions are possible. Central depressant drugs and alcohol may potentiate the adverse effects of carisoprodol.
Adverse effects
The most common possible adverse effects include drowsiness , dizziness , and headache .
